Abstract
Objective: The main objective is to estimate the spatial resolution of brain PET images.
Background: The spatial resolution of brain PET images is often estimated using Hoffman phantom data. Unfortunately, Hoffman phantom images may not always be readily available, and phantom-based approaches may yield sub-optimal results. We propose a new, computational approach that allows estimation of spatial resolution directly from the PET image itself.
Design/Methods: We generalized the logarithmic intensity plots reported by Mizutani and colleagues (Mizutani, 2016) in order to perform spatial resolution estimation in both axial and in-plane directions. The FWHMs are estimated from multiple regression of the logarithm of the square norm of the image Fourier transform against the square distance from the origin in the Fourier domain. The proposed approach was applied to Amyloid and FDG PET images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study.
Results: We obtained in-plane and axial FWHMs resolution estimators that vary between 3.5 mm and 8 mm for both [18F]florbetapir and [18F]FDG images. In both cases, we observed a low within-scan variability. We also obtained a strong cross-tracer consistency in FWHM resolution estimators, which is an expected result since the spatial resolution does not depend on the particular 18F-labeled tracer.
Conclusions: We obtained small (less than a voxel size) across-subject variability in groups of subjects sharing the same PET site and reconstruction parameters. Our novel approach not only eliminates the need for surrogate brain phantom data, but also provides a general framework that can be applied to a wide range of tracers and other image modalities, such as SPECT.
Disclosure: Dr. Carbonell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biospective Inc.. Dr. Zijdenbos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biospective Inc.. Dr. Zijdenbos holds stock and/or stock options in Biospective Inc. which sponsored research in which Dr. Zijdenbos was involved as an investigator. Dr. Bedell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee: Biospective Inc.. Dr. Bedell holds stock and/or stock options in Stock: Biospective Inc. which sponsored research in which Dr. Bedell was involved as an investigator.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.